848 related articles for article (PubMed ID: 32213540)
21. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab Deruxtecan DESTINY for Some Cancers.
Cancer Discov; 2020 Jul; 10(7):898. PubMed ID: 32487568
[TBL] [Abstract][Full Text] [Related]
23. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
[TBL] [Abstract][Full Text] [Related]
25. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
[TBL] [Abstract][Full Text] [Related]
28. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
31. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
[TBL] [Abstract][Full Text] [Related]
32. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab deruxtecan in breast cancer.
Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
[TBL] [Abstract][Full Text] [Related]
37. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
[TBL] [Abstract][Full Text] [Related]
38. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
39. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
40. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
